News
Boehringer Ingelheim entered into a collabration agreement with VTU Technology
Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive technologies and comprehensive services for the development of high-performance Pichia pastoris protein expression strains, announced today that they have entered...
News
Columbia Asia performs its first stem cell transplant
Columbia Asia Hospital - Yeshwanthpur in Bangalore performed its first stem cell transplant recently. The Times of India featured the procedure this week and described how a 44-year-old Swiss man was unable to walk without help until he came...
News
IntegenX Launches the Apollo 324 System for Automated DNA
IntegenX Inc(IXI) at the 60th Annual American Society of Human Genetics Meeting announced the launch of their Apollo 324 System, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation sequencing. The system can prepare...
News
Merck To Present Innovative Products for Displays at the FPD International in Makuhari (Japan)
Merck KGaA announced today that it will be exhibiting at the FPD International, one of the leading events for the flat panel display industry, from November 10 to 12, 2010 in Makuhari / Chiba, (Japan). The ...
News
Eli Lilly and Company received FDA approval for Cymbalta
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain and...
News
Eli Lilly to Open a Diabetes-Focused Research Center in China
Eli Lilly and Company announced plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions. The center, to open in Shanghai in the second half of 2011, will...
News
GlaxoSmithKline receives approval in Japan from the Ministry of Health
GlaxoSmithKline announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP), and for Xyzal (levocetirizine dihydrochloride), the first...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
